$1.95
0.51% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US0053291078
Symbol
ADAG
Sector
Industry

Adagene Inc - ADR Stock price

$1.95
+0.23 13.37% 1M
-0.11 5.34% 6M
-0.04 2.01% YTD
-0.86 30.61% 1Y
-28.04 93.50% 5Y
-28.04 93.50% 10Y
-28.04 93.50% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.01 0.51%
ISIN
US0053291078
Symbol
ADAG
Sector
Industry

Key metrics

Market capitalization $93.28m
Enterprise Value $26.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 262.97
P/S ratio (TTM) P/S ratio 932.77
P/B ratio (TTM) P/B ratio 2.28
Revenue growth (TTM) Revenue growth -99.45%
Revenue (TTM) Revenue $100.00k
EBIT (operating result TTM) EBIT $-35.95m
Free Cash Flow (TTM) Free Cash Flow $-29.73m
Cash position $85.19m
EPS (TTM) EPS $-0.59
P/E forward negative
P/S forward 2,798.43
EV/Sales forward 789.01
Short interest 0.18%
Show more

Is Adagene Inc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Adagene Inc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Adagene Inc - ADR forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Adagene Inc - ADR forecast:

Buy
33%
Hold
67%

Financial data from Adagene Inc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.10 0.10
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.27 7.27
16% 16%
7,270%
- Research and Development Expense 29 29
21% 21%
28,780%
-35 -35
-
-35,230%
- Depreciation and Amortization 0.72 0.72
-
720%
EBIT (Operating Income) EBIT -36 -36
52% 52%
-35,952%
Net Profit -33 -33
76% 76%
-33,420%

In millions USD.

Don't miss a Thing! We will send you all news about Adagene Inc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagene Inc - ADR Stock News

Neutral
GlobeNewsWire
18 days ago
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place...
Neutral
GlobeNewsWire
about 2 months ago
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their pr...
More Adagene Inc - ADR News

Company Profile

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Head office Cayman Islands
CEO Peizhi Luo
Employees 138
Founded 2011
Website www.adagene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today